A

Altimmune

D
ALT
USD
0.155
(2.1218%)
Market Closed
186,960.00
Volume
-1.25
EPS
-
Div Yield
-4.570552
P/E
530,189,294.46
Market Cap
Today
2.1218%
1 Week
10.519%
1 Month
22.095%
6 Months
2.473%
12 Months
174.265%
Year To Date
-33.718%
All Time
-99.143%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
0.0001490405
(0.4045%)
USD

Title:
Altimmune

Sector:
Healthcare
Industry:
Biotechnology
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Do you need help or have a question?
Contact Us